News & Updates
Filter by Specialty:
Bevacizumab + EGFR-TKI improves OS in EGFR-mutated NSCLC with leptomeningeal metastases
Adding bevacizumab to an EGFR tyrosine kinase inhibitor (TKI) improves overall survival (OS) in adult patients with EGFR-mutated non-small-cell lung cancer (NSCLC) and leptomeningeal metastases (LMs), according to a single-centre, retrospective, real-world study in China. OS was, however, similar between patients on chemotherapy plus EGFR-TKI and those on EGFR-TKI monotherapy.
Bevacizumab + EGFR-TKI improves OS in EGFR-mutated NSCLC with leptomeningeal metastases
20 Mar 2024Are heat-related illnesses in SG a cause for alarm?
Unique features characterize the occurrence of heat-related illnesses, such as cramps, exhaustion, and stroke, among patients admitted to the emergency department (ED) of Singapore General Hospital, reports a recent study.
Are heat-related illnesses in SG a cause for alarm?
05 Mar 2024Glaucoma tied to increased risk of Alzheimer's, related dementias
Individuals with glaucoma, particular those diagnosed at older ages, are prone to developing Alzheimer’s disease (AD), vascular dementia (VaD), and all-cause dementia (ACD), reports a study.
Glaucoma tied to increased risk of Alzheimer's, related dementias
01 Mar 2024Interactive multistage robotic positioner developed for intraoperative MRI-guided stereotactic neurosurgery
A joint multidisciplinary team of researchers from the Chinese University of Hong Kong (CUHK), the University of Hong Kong (HKU), University College London, and Johns Hopkins University has developed an interactive, multistage robotic positioner for intraoperative MRI-guided stereotactic neurosurgery aimed at treating patients with neurological diseases, such as brain tumours and Parkinson’s disease.
Interactive multistage robotic positioner developed for intraoperative MRI-guided stereotactic neurosurgery
01 Mar 2024Cilostazol, ticagrelor more cost-effective than standard therapy for acute ischaemic stroke
Use of CYP2C19 genotype-guided antiplatelet therapy with cilostazol or ticagrelor as a substitute to clopidogrel is more cost-effective than conventional antiplatelet therapy for patients with acute minor ischaemic stroke and high-risk transient ischaemic attack, suggests a China study.